UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 20, 2007
AngioGenex, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-26181 86-0945116
---------------------------- ------------ ------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
425 Madison Avenue, Suite 902, New York N.Y. 10017
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
(212) 874-6608 (212) 874-5027
-----------------------------------------
Issuer's Telephone Number Fax
Not applicable
--------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
===============================================================================
ITEM 7.01. Regulation FD Disclosure.
AngioGenex, Inc. ("the Registrant") issued a press release on June 20, 2007
regarding the Registrant's European Listing on the Frankfurt Stock Exchange
under Symbol "TLE." A copy of the press release is attached as Exhibit 99.9
to this Form 8-K and is incorporated herein by reference.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.9 Press Release dated June 20, 2007, regarding trading symbol and
description of Registrant's business.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AngioGenex, Inc.
-------------------------
Registrant
By: /s/ Richard Salvador
-------------------------
Name: Richard Salvador
Title: President/CEO
Dated: June 20, 2007
2
Exhibit Index
99.7* Press Release, dated March 7, 2007.
- ---------------
*this filing